MOF-Based Arginine Nanocarriers for Coordinated Immunometabolic and Antitumor Modulation in Triple Negative Breast Cancer

Key Points

• The aim is to investigate the effectiveness of MOF-based arginine nanocarriers in enhancing immunometabolic responses and antitumor effects.
• Utilized MOF-based nanocarriers to deliver L-arginine effectively in cancer cells
• Assessed immunological and metabolic impacts in triple negative breast cancer models
• Measured changes in nitric oxide levels and tumor growth reduction.
• Enhanced bioavailability of L-arginine through the nanocarriers
• Improved responses of immune cells and reduced tumor size
• Demonstrated potential for better therapeutic outcomes in triple negative breast cancer.